Effects of Intrathecal Dexmedetomidine as an Adjuvant to Low Dose Hyperbaric 0.5% Bupivacaine
Post Operative Pain
About this trial
This is an interventional supportive care trial for Post Operative Pain
Eligibility Criteria
Inclusion Criteria: ASA I to ASA II Age 50 to 80 years old Height between 155cm and 175 cm Exclusion Criteria: History of spine surgery or the presence of an infectious focus on the back Patient's refusal to undergo a spinal anaesthesia Hypersensitivity to bupivacaine or dexmedetomidine Patients taking drugs of abuse or narcotic analgesics Diabetic neuropathy History of bleeding disorders Oral/intravenous anticoagulant therapy History of arrhythmias or labile hypertension Unco-operative patients Hearing defect ASA III and IV Central or peripheral nervous system disorders Severe hypovolemia
Sites / Locations
- Syed Muhammad Abbas
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Bupivacaine 0.5%
BUPI-DEX
Hyperbaric Bupivacaine 0.5% (2.5 ml/12.5 mg) to be given intrathecally Total volume 2.5 mL
Hyperbaric Bupivacaine 0.5% (1.5 ml/7.5 mg)+Dexmedetomidine (1 mL) 5 microgram intrathecally. Total volume 2.5 mL